Waldenstrom MacroglobulinaemiaNCT07160270
This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process
An observational study of Waldenstrom Macroglobulinaemia and Peripheral Neuropathies, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
Trial summary
Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs. Given the diverse origins of neuropathy, it is critical to identify its specific causes, particularly when effective treatments are available. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Waldenstrom Macroglobulinaemia, Peripheral Neuropathies
- How many people
- 90 participants
- Where
- 1 siteDenmark
- Study dates
- 14 May 2025to 30 Dec 2025
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Active diagnose of Waldenström's Macroglobulinemia under follow-up or has been followed at Rigshospitalet Department of Hematology.
Who may be able to join
- Diagnosis of Waldenström's Macroglobulinemia with symptoms of peripheral neuropathy for further clinical investigation.
Who cannot join
- Investigated with no sign of peripheral neuropathy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Copenhagen Neuromuscular Center, Rigshospitalet Blegdamsvej.
København Ø, 2100
Morten Müller Aagaard, +4521671835, morten.mueller.aagaard.01@regionh.dk
About this study
Official title: Neuropathy in Waldenström's Macroglobulinemia: Pathophysiology, Prognosis and Treatment
Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs. Given the diverse origins of neuropathy, it is critical to identify its specific causes, particularly when effective treatments are available. Neuropathy is a frequent morbidity in Waldenström's macroglobulinemia (WM), a specific type of lymphoma caused by infiltration of clonal lymphoplasmocytic B cells in the bone marrow with the presence of IgM paraprotein. WM associated neuropathy is largely undescribed. The few existing studies are mostly retrospective indicating the neuropathy has a heterogenic pathophysiology and diverse clinical appearance from mild sensory neuropathy to aggressive with loss of ambulation and development of chronic neuropathic pain within weeks to months.
With treatment of WM the speed of the disease progression including the related neuropathy can be halted. Few studies and clinical experience indicate that the nerve damage induced by WM might remit if treatment is initiated early in the course of the disease. Thus, there is need for timely interventions to reduce chronic disabilities. However, even for an experienced neurologist, it can be difficult to identify whether the neuropathy is caused by WM or other causes where treatment is not indicated.
This project aims to investigate the prevalence and underlying mechanisms of neuropathy in patients with WM to help speed up the diagnostic process and thus help slow down the irreversible nerve damage that these patients experience.
Read the detailed description
Methods
Study design: Cross-sectional observations study
Outcome:
Prevalence: Determining how many WM patients have neuropathy.
Characterization: Identification of clinical subtypes of WM associated neuropathy and their symptoms.
Biomarkers: Establishing relevant biomarkers (e.g., neurofilament light chain) to diagnose and predict neuropathy outcome.
We have already identified all patients with an active diagnosis of Waldenström Macroglobulinemia followed at the Department of Haematology at Rigshospitalet in august 2024. All patients have been screened with a questionnaire designed to identify signs of neuropathy. If probable symptoms of neuropathy the patients will be examined in the Department of Neurology. Almost 600 patients has been invided. 100 patients have symptoms fulfilling the criteria for probable neuropathy. With expect 90 patients patients in total to undergo clinical examination. Neuropathy will be clinically classified and confirmed with a nerve conduction study (ENG). Patient with neuropathy associated to WM will be further investigated with blood samples and lumbar puncture. The study duration will be one year, where we expect all participants to have gone through questionnaire, clinical examination, nerve conduction study and paraclinical tests. The follow up period will be for 3 years.
Clinical examination will be done by the responsible investigator Morten Müller Aagaard, MD.
Methodes include:
- Clinical examination Neurological examination by a trained physician within the field of neuropathy.
- Nerve conduction study (ENG) Paraclinical test of the sensory- and motornerves of the peripheral nervous system.
- Questionnaires: I-RODS, FES-I, COMPASS 31, FSS and 5Q-5D
- Blood samples The blood samples will be analysed with a standard polyneuropathy panel (liver, blood sugar/diabetes, kidney and hematologic markers e.g. interleukin-6, immunoglobulin A, G and M, kappa/lambda-chains and M-protein). Additionally the samples will be analysed for paraneoplastic antibodies, marker of neurodegenerative processes (e.g. neurofilament), rheumatologic markers (SSA, SSB, cryoglobulin, SR), and infection disorders as hepatitis b + c antibodies and HIV. In collaboration with department of immunology we also want to examine samples for complement activity and inflammation markers including cytokines. Whole genome squencing (WGS) for inherited neuropathies.
- Cerebrospinal fluid
Cerebrospinal fluid will be examined with standard tests (erythrocytes, leucocytes, glucose, protein, neurofilament light polypeptide, borrelia, flowcytometry, cytology, and CXCL13)
The study duration will be 1 year with extra follow up for 3 years.
Statistics
The study is designed as a cross-sectional observation study describing WM associated neuropathy. The prevalence of neuropathy associated to WM will be estimated. Non-responders will be classified as missing data at random. In addition, sensitivity analyses will be conducted where the prevalence of neuropathy in non-responders will be varied within reasonable range and combined with information from the responders. Data will be processed using standard descriptive statistics, comparing results with normative reference values. Differences between WM patients and normal material will be analysed using t-tests, with p-values <0.05 considered statistically significant. The types of neuropathies, defined through electrophysiological and clinical phenotypes will undergo subgroup analyses based on group sizes. Statistical differences in clinical outcomes and biomarkers will be examined using ANOVA tests.
Impact
- Clinical Understanding Enhanced Knowledge: The study will improve understanding of the prevalence, types, and pathophysiology of neuropathy associated with WM, leading to better recognition of the condition among healthcare providers. Treatment Guidelines: Establish clinical markers that may contribute to initiating or intensifying treatment for neuropathy associated with WM.
- Patient Management Improved Diagnosis: Identification of specific biomarkers and clinical indicators will facilitate earlier and more accurate diagnoses of neuropathy, allowing for timely intervention. Optimal Monitoring: Contributing to better surveillance and management of WM regarding development of neuropathy in clinical practice. Tailored Treatments: Insights into which patients are likely to benefit from specific treatments can lead to studies about more personalized and effective treatment strategies.
- Quality of Life
Functional Preservation: Addressing neuropathy early will lead to more rapid interventions both treatment and focus on the disabilities. Thus, patients may experience better maintenance of their mobility and daily functioning, thereby improving their overall quality of life.
- Medical subject headings
- Waldenstrom Macroglobulinemia, Peripheral Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Neuropathy associated to Waldenström's Macroglobulinemia | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of peripheral neuropathy associated to Waldenström Macroglobulinema (WM)
The prevalence will be calculated by screening WM patients with a questionnaire designed specific for the research project to identify possible peripheral neuropathy. Patients with possible peripheral neuropathy will be clinical examined to either positiv og negative for peripheral neuropathy and confirmed by nerve conduction study. The prevalence will be the amount of patient with polyneuropathy in the population of investigated patientes with WM.
Measured: From enrollment from August 2024 and new diagnosed patients with WM and symptoms of neuropathy refered to the neuromuscular clinic until July 2025.
Secondary outcomes (1)
Disability of WM associated polyneuropathy
The severity of WM associated neuropathy will be assesed by neuropathy scores - INCAT disability score (a scale of 0-10 with higher scores indicating greater disability.)
- MRC 80 sum score (0-80. Lower score indicating more severe paralysis)
- INCAT sensory sum score (0-20 with with higher scores indicating greater sensory abnormalities)
- Modified Rankin scale: numbered 0 to 6, with higher scores indicating greater disability.
Measured: Investigation during one year with follow up for 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start14 May 2025
- Primary completion30 Dec 2025 (estimated)
- Study completion30 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Waldenstrom MacroglobulinaemiaStudies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Morten Müller Aagaard, Copenhagen University Hospital, Rigshospitalet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07160270
- Sponsor's protocol ID
- H-23064477
- Status last verified
- Aug 2025
- First submitted
- 2 Jun 2025
- Last updated
- 8 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naive patients. Semin Hematol. 2023 Mar;60(2):73-79. doi: 10.1053/j.seminhematol.2023.03.005. Epub 2023 Mar 29.
PubMed 37099027D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 Mar;176(5):728-742. doi: 10.1111/bjh.14492. Epub 2017 Feb 15.
PubMed 28198999Treon SP, Hanzis CA, Ioakimidis LI, Patterson CJ, Hunter ZR, Brodsky PS, m.fl. Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM). J Clin Oncol. 20. maj 2010;28(15_suppl):8114-8114.
Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology. 2016 Nov 1;87(18):1892-1898. doi: 10.1212/WNL.0000000000003293. Epub 2016 Sep 28.
PubMed 27683845Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcia-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15.
PubMed 25027391Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21.
PubMed 26686858Viala K, Stojkovic T, Doncker AV, Maisonobe T, Lenglet T, Bruneteau G, Musset L, Neil J, Leger JM, Leblond V. Heterogeneous spectrum of neuropathies in Waldenstrom's macroglobulinemia: a diagnostic strategy to optimize their management. J Peripher Nerv Syst. 2012 Mar;17(1):90-101. doi: 10.1111/j.1529-8027.2012.00376.x.
PubMed 22462670Levine T, Pestronk A, Florence J, Al-Lozi MT, Lopate G, Miller T, Ramneantu I, Waheed W, Stambuk M, Stone MJ, Choksi R. Peripheral neuropathies in Waldenstrom's macroglobulinaemia. J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):224-8. doi: 10.1136/jnnp.2005.071175.
PubMed 16421127Tomkins O, Leblond V, Lunn MP, Viala K, Weil DR, D'Sa S. Investigation and Management of Immunoglobulin M- and Waldenstrom-Associated Peripheral Neuropathies. Hematol Oncol Clin North Am. 2023 Aug;37(4):761-776. doi: 10.1016/j.hoc.2023.04.007.
PubMed 37385714Bibas M, Sarosiek S, Castillo JJ. Waldenstrom Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems. Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024061. doi: 10.4084/MJHID.2024.061. eCollection 2024.
PubMed 38984103Racine M. Chronic pain and suicide risk: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt B):269-280. doi: 10.1016/j.pnpbp.2017.08.020. Epub 2017 Aug 26.
PubMed 28847525Damci A, Schruers KRJ, Leue C, Faber CG, Hoeijmakers JGJ. Anxiety and depression in small fiber neuropathy. J Peripher Nerv Syst. 2022 Dec;27(4):291-301. doi: 10.1111/jns.12514. Epub 2022 Oct 7.
PubMed 36168866Streckmann F, Balke M, Cavaletti G, Toscanelli A, Bloch W, Decard BF, Lehmann HC, Faude O. Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Med. 2022 May;52(5):1043-1065. doi: 10.1007/s40279-021-01596-6. Epub 2021 Dec 29.
PubMed 34964950Girach A, Julian TH, Varrassi G, Paladini A, Vadalouka A, Zis P. Quality of Life in Painful Peripheral Neuropathies: A Systematic Review. Pain Res Manag. 2019 May 23;2019:2091960. doi: 10.1155/2019/2091960. eCollection 2019.
PubMed 31249636
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neuropathy in Waldenström's Macroglobulinemia: Pathophysiology, Prognosis and Treatment
- ClinicalTrials.gov ID
- NCT07160270
- Acronym / sponsor ID
- H-23064477
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Study start
- 14 May 2025 (actual)
- Primary completion
- 30 Dec 2025 (estimated)
- Study completion
- 30 Dec 2025 (estimated)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs. Given the diverse origins of neuropathy, it is critical to identify its specific causes, particularly when effective treatments are available. Neuropathy is a frequent morbidity in Waldenström's macroglobulinemia (WM), a specific type of lymphoma caused by infiltration of clonal lymphoplasmocytic B cells in the bone marrow with the presence of IgM paraprotein. WM associated neuropathy is largely undescribed. The few existing studies are mostly retrospective indicating the neuropathy has a heterogenic pathophysiology and diverse clinical appearance from mild sensory neuropathy to aggressive with loss of ambulation and development of chronic neuropathic pain within weeks to months.
With treatment of WM the speed of the disease progression including the related neuropathy can be halted. Few studies and clinical experience indicate that the nerve damage induced by WM might remit if treatment is initiated early in the course of the disease. Thus, there is need for timely interventions to reduce chronic disabilities. However, even for an experienced neurologist, it can be difficult to identify whether the neuropathy is caused by WM or other causes where treatment is not indicated.
This project aims to investigate the prevalence and underlying mechanisms of neuropathy in patients with WM to help speed up the diagnostic process and thus help slow down the irreversible nerve damage that these patients experience.
Detailed description
Methods
Study design: Cross-sectional observations study
Outcome:
Prevalence: Determining how many WM patients have neuropathy.
Characterization: Identification of clinical subtypes of WM associated neuropathy and their symptoms.
Biomarkers: Establishing relevant biomarkers (e.g., neurofilament light chain) to diagnose and predict neuropathy outcome.
We have already identified all patients with an active diagnosis of Waldenström Macroglobulinemia followed at the Department of Haematology at Rigshospitalet in august 2024. All patients have been screened with a questionnaire designed to identify signs of neuropathy. If probable symptoms of neuropathy the patients will be examined in the Department of Neurology. Almost 600 patients has been invided. 100 patients have symptoms fulfilling the criteria for probable neuropathy. With expect 90 patients patients in total to undergo clinical examination. Neuropathy will be clinically classified and confirmed with a nerve conduction study (ENG). Patient with neuropathy associated to WM will be further investigated with blood samples and lumbar puncture. The study duration will be one year, where we expect all participants to have gone through questionnaire, clinical examination, nerve conduction study and paraclinical tests. The follow up period will be for 3 years.
Clinical examination will be done by the responsible investigator Morten Müller Aagaard, MD.
Methodes include:
- Clinical examination Neurological examination by a trained physician within the field of neuropathy.
- Nerve conduction study (ENG) Paraclinical test of the sensory- and motornerves of the peripheral nervous system.
- Questionnaires: I-RODS, FES-I, COMPASS 31, FSS and 5Q-5D
- Blood samples The blood samples will be analysed with a standard polyneuropathy panel (liver, blood sugar/diabetes, kidney and hematologic markers e.g. interleukin-6, immunoglobulin A, G and M, kappa/lambda-chains and M-protein). Additionally the samples will be analysed for paraneoplastic antibodies, marker of neurodegenerative processes (e.g. neurofilament), rheumatologic markers (SSA, SSB, cryoglobulin, SR), and infection disorders as hepatitis b + c antibodies and HIV. In collaboration with department of immunology we also want to examine samples for complement activity and inflammation markers including cytokines. Whole genome squencing (WGS) for inherited neuropathies.
- Cerebrospinal fluid
Cerebrospinal fluid will be examined with standard tests (erythrocytes, leucocytes, glucose, protein, neurofilament light polypeptide, borrelia, flowcytometry, cytology, and CXCL13)
The study duration will be 1 year with extra follow up for 3 years.
Statistics
The study is designed as a cross-sectional observation study describing WM associated neuropathy. The prevalence of neuropathy associated to WM will be estimated. Non-responders will be classified as missing data at random. In addition, sensitivity analyses will be conducted where the prevalence of neuropathy in non-responders will be varied within reasonable range and combined with information from the responders. Data will be processed using standard descriptive statistics, comparing results with normative reference values. Differences between WM patients and normal material will be analysed using t-tests, with p-values <0.05 considered statistically significant. The types of neuropathies, defined through electrophysiological and clinical phenotypes will undergo subgroup analyses based on group sizes. Statistical differences in clinical outcomes and biomarkers will be examined using ANOVA tests.
Impact
- Clinical Understanding Enhanced Knowledge: The study will improve understanding of the prevalence, types, and pathophysiology of neuropathy associated with WM, leading to better recognition of the condition among healthcare providers. Treatment Guidelines: Establish clinical markers that may contribute to initiating or intensifying treatment for neuropathy associated with WM.
- Patient Management Improved Diagnosis: Identification of specific biomarkers and clinical indicators will facilitate earlier and more accurate diagnoses of neuropathy, allowing for timely intervention. Optimal Monitoring: Contributing to better surveillance and management of WM regarding development of neuropathy in clinical practice. Tailored Treatments: Insights into which patients are likely to benefit from specific treatments can lead to studies about more personalized and effective treatment strategies.
- Quality of Life
Functional Preservation: Addressing neuropathy early will lead to more rapid interventions both treatment and focus on the disabilities. Thus, patients may experience better maintenance of their mobility and daily functioning, thereby improving their overall quality of life.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Neuropathy associated to Waldenström's Macroglobulinemia | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Active diagnose of Waldenström's Macroglobulinemia under follow-up or has been followed at Rigshospitalet Department of Hematology.
Key inclusion criteria (1 listed)
- Diagnosis of Waldenström's Macroglobulinemia with symptoms of peripheral neuropathy for further clinical investigation.
Key exclusion criteria (1 listed)
- Investigated with no sign of peripheral neuropathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of peripheral neuropathy associated to Waldenström Macroglobulinema (WM)
Time frame: From enrollment from August 2024 and new diagnosed patients with WM and symptoms of neuropathy refered to the neuromuscular clinic until July 2025.
The prevalence will be calculated by screening WM patients with a questionnaire designed specific for the research project to identify possible peripheral neuropathy. Patients with possible peripheral neuropathy will be clinical examined to either positiv og negative for peripheral neuropathy and confirmed by nerve conduction study. The prevalence will be the amount of patient with polyneuropathy in the population of investigated patientes with WM.
1 secondary outcome
Disability of WM associated polyneuropathy
Time frame: Investigation during one year with follow up for 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2025.
- Background: PubMed 37099027Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naive patients. Semin Hematol. 2023 Mar;60(2):73-79. doi: 10.1053/j.seminhematol.2023.03.005. Epub 2023 Mar 29.
- Background: PubMed 28198999D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 Mar;176(5):728-742. doi: 10.1111/bjh.14492. Epub 2017 Feb 15.
- BackgroundTreon SP, Hanzis CA, Ioakimidis LI, Patterson CJ, Hunter ZR, Brodsky PS, m.fl. Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM). J Clin Oncol. 20. maj 2010;28(15_suppl):8114-8114.
- Background: PubMed 27683845Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology. 2016 Nov 1;87(18):1892-1898. doi: 10.1212/WNL.0000000000003293. Epub 2016 Sep 28.
- Background: PubMed 25027391Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcia-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15.
- Background: PubMed 26686858Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21.
- Background: PubMed 22462670Viala K, Stojkovic T, Doncker AV, Maisonobe T, Lenglet T, Bruneteau G, Musset L, Neil J, Leger JM, Leblond V. Heterogeneous spectrum of neuropathies in Waldenstrom's macroglobulinemia: a diagnostic strategy to optimize their management. J Peripher Nerv Syst. 2012 Mar;17(1):90-101. doi: 10.1111/j.1529-8027.2012.00376.x.
- Background: PubMed 16421127Levine T, Pestronk A, Florence J, Al-Lozi MT, Lopate G, Miller T, Ramneantu I, Waheed W, Stambuk M, Stone MJ, Choksi R. Peripheral neuropathies in Waldenstrom's macroglobulinaemia. J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):224-8. doi: 10.1136/jnnp.2005.071175.
- Background: PubMed 37385714Tomkins O, Leblond V, Lunn MP, Viala K, Weil DR, D'Sa S. Investigation and Management of Immunoglobulin M- and Waldenstrom-Associated Peripheral Neuropathies. Hematol Oncol Clin North Am. 2023 Aug;37(4):761-776. doi: 10.1016/j.hoc.2023.04.007.
- Background: PubMed 38984103Bibas M, Sarosiek S, Castillo JJ. Waldenstrom Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems. Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024061. doi: 10.4084/MJHID.2024.061. eCollection 2024.
- Background: PubMed 28847525Racine M. Chronic pain and suicide risk: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt B):269-280. doi: 10.1016/j.pnpbp.2017.08.020. Epub 2017 Aug 26.
- Background: PubMed 36168866Damci A, Schruers KRJ, Leue C, Faber CG, Hoeijmakers JGJ. Anxiety and depression in small fiber neuropathy. J Peripher Nerv Syst. 2022 Dec;27(4):291-301. doi: 10.1111/jns.12514. Epub 2022 Oct 7.
- Individual participant dataSharing planned: Undecided
Related trials for Waldenstrom Macroglobulinaemia
RecruitingObservational study
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
RecruitingPhase 1/2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Lymphoma, Waldenström Macroglobulinemia (WM)
RecruitingPhase 2
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
RecruitingPhase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Active, not recruitingPhase 1
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Waldenstrom Macroglobulinaemia and Peripheral Neuropathies, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Morten Müller Aagaard, Medical Doctor (+4521671835, morten.mueller.aagaard.01@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of peripheral neuropathy associated to Waldenström Macroglobulinema (WM) (time frame: From enrollment from August 2024 and new diagnosed patients with WM and symptoms of neuropathy refered to the neuromuscular clinic until July 2025.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07160270, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2025.